You just read:

U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Oct 30, 2018, 08:45 ET